Thrombin Activatable Fibrinolysis Inhibitor (TAFI) A Link between Coagulationand Fibrinolysis
Jovan P. Antovic
Clinical Laboratory 49(9-10): 475-486
2003
ISSN/ISBN: 1433-6510 PMID: 14572204 Document Number: 10224
Document emailed within 1 workday
Related Documents
Brouwers, G-Jan.; Leebeek, F.W.G.; Tanck, M.W.T.; Wouter Jukema, J.; Kluft, C.; de Maat, M.P.M. 2003: Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris Thrombosis and Haemostasis 90(1): 92-100Colucci, M.; Pentimone, A.; Binetti, B.M.; Cramarossa, M.; Piro, D.; Semeraro, N. 2002: Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin Thrombosis and Haemostasis 88(2): 282-287
Vorob'eva, N.M.; Panchenko, E.P.; Dobrovol'skiĭ, A.B.; Titaeva, E.V.; Ermolina, O.V.; Balakhonova, T.V.; Khasanova, Z.B.; Postnov, A.I.; Kirienko, A.I. 2011: Thrombin-activated inhibitor of fibrinolysis and efficacy and safety of long-term warfarin treatment in patients with venous thromboembolic complications Terapevticheskii Arkhiv 83(12): 43-48
Monteagudo, J.; Pereira, A.; Reverter, J.C.; Pijoan, J.; Tusell, J.; Puig, L.; Ordinas, A.; Castillo, R. 1991: Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome Thrombosis and Haemostasis 66(5): 515-519
Munkvad, S. 1993: Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways Danish Medical Bulletin 40(4): 383-408
Schneider, J.; Hauser, R.; Hennies, H.H.; Korioth, J.; Steffens, G.; Wnendt, S. 1997: A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs Thrombosis and Haemostasis 77(3): 535-539
Fantoni, A.; Cassolini, G.M.; Gobbi, F.; Chiappa, A.; Turinetti, C.; Julitta, R. 1981: Determination of fibrinolysis inhibitor activity in pregnancy. Preparation of plasminogen Archivio Per le Scienze Mediche 138(2): 199-200
Liapina, L.A.; Ammosova, I.M. 1987: Complex formation of heparin with the inhibitor of non-enzymatic fibrinolysis isolated from the spleen Voprosy Meditsinskoi Khimii 33(3): 88-91
Kuznik, B.I.; Tsybikov, N.N.; Budazhapova, D.T.; Zagrebina, L.A.; Mishchenko, V.P. 1983: Effect of combined administration of thrombin and heterologous blood on blood coagulation and fibrinolysis in dogs Gematologiia i Transfuziologiia 28(9): 40-44
Nicoloso, G.; Hauert, J.; Kruithof, E.K.; Van Melle, G.; Bachmann, F. 1988: Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system Thrombosis and Haemostasis 59(2): 299-303
De Clerck, F.; Vermylen, J.; Reneman, R. 1975: Effects of suprofen, an inhibitor of prostaglandin biosynthesis, on platelet function, plasma coagulation and fibrinolysis. I. in vitro experiments Archives Internationales de Pharmacodynamie et de Therapie 216(2): 263-279
Humphries, S.E.; Lane, A.; Dawson, S.; Green, F.R. 1992: The study of gene-environment interactions that influence thrombosis and fibrinolysis. Genetic variation at the loci for factor VIi and plasminogen activator inhibitor-1 Archives of Pathology and Laboratory Medicine 116(12): 1322-1329
Nizankowski, R.; Krzanowski, M.; Musiał, J.; Szczeklik, A. 1991: Effect of thromboxane A2 synthetase inhibitor and prostacyclin analogue on arterial blood pressure, fibrinolysis and platelet function in patients with hypertension Polski Tygodnik Lekarski 46(1-3): 18-21
Avikainen, V.; Eklund, B. 1974: Disseminated intravascular coagulation after inhibition of fibrinolysis with tranexamic acid (AMCA) and proteinase inhibitor Trasylol in experimental traumatic and haemorrhagic shock Annales Chirurgiae et Gynaecologiae Fenniae 63(3): 226-234
Ichinose, A.; Sakata, Y.; Aoki, N. 1982: Reactions of alpha 2 plasmin inhibitor to plasmin and fibrin; its significance in fibrinolysis inhibition and hemostasis Rinsho Byori. Japanese Journal of Clinical Pathology Suppl 50: 178-188
Aoki, N. 1993: Clot retraction increases clot resistance to fibrinolysis by condensing alpha 2-plasmin inhibitor crosslinked to fibrin Thrombosis and Haemostasis 70(2): 376
Dudek, D.; Bartuś, Sław.; Zmudka, K.; Kuta, M.; Legutko, J.; Wizimirski, M.; Pieniazek, P.; Przewłocki, T.; Gajos, G.; Bryniarski, L.; Dragan, J.; Pasowicz, Mław.; Zorkun, C.; Dubiel, J.S. 2002: Assessment of myocardial reperfusion in patients with acute myocardial infarction treated with combination of fibrinolysis and IIb/IIIa platelet inhibitor Przeglad Lekarski 59(1): 1-6
Glas-Greenwalt, P.; Hall, J.M.; Panke, T.W.; Kant, K.S.; Allen, C.M.; Pollak, V.E. 1986: Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura Journal of Laboratory and Clinical Medicine 108(5): 415-422
Schroeder, V.; Wilmer, M.; Buehler, B.; Kohler, H.P. 2006: TAFI activity in coronary artery disease: a contribution to the current discussion on TAFI assays Thrombosis and Haemostasis 96(2): 236-237
Dzhurdzhev, A.; Atanasov, K. 1981: Nonenzymatic fibrinolysis Vutreshni Bolesti 20(3): 18-22